All Releases
 |
Capstone Therapeutics Announces Transfer to Nasdaq Capital Market
Nov 17, 2009
|
15.9 KB |
|
| |
TEMPE, Ariz., Nov 17, 2009 (GlobeNewswire via COMTEX News Network) -- Capstone Therapeutics (the "Company") (Nasdaq:CAPS) today announced that its application to transfer the listing of its common stock from The Nasdaq Global Market to The Nasdaq Capital Market has been approved by Nasdaq. This transfer will be effective at the opening of business ...
|
|
Capstone Therapeutics Announces Third Quarter 2009 Financial Results
Nov 9, 2009
|
19.9 KB |
|
| |
TEMPE, Ariz., Nov 9, 2009 (GlobeNewswire via COMTEX News Network) -- Capstone Therapeutics (Nasdaq:CAPS), trade name of OrthoLogic Corp. (the "Company"), today announced financial results for the third quarter 2009.
The Company reported a net loss of $3.3 million, or $0.08 per share, for the third quarter 2009, compared to a net loss of $3.1 mi...
|
|
Capstone Therapeutics to Host Conference Call Discussing Third Quarter 2009 Operating Results
Nov 4, 2009
|
15.5 KB |
|
| |
TEMPE, Az., Nov 4, 2009 (GlobeNewswire via COMTEX News Network) -- Capstone Therapeutics (Nasdaq:CAPS), trade name of OrthoLogic Corp. (the "Company"), will host a conference call and webcast presenting third quarter 2009 operating results on Monday, November 9, 2009 at 4:30pm EST / 3:30pm CST / 2:30pm MST / 1:30pm PST. The call may be accessed at ...
|
|
Capstone Therapeutics to Present at 4th Annual BIOCOM Investor Conference
Oct 22, 2009
|
15.7 KB |
|
| |
TEMPE, Ariz., Oct 22, 2009 (GlobeNewswire via COMTEX News Network) -- Capstone Therapeutics (Nasdaq:CAPS) is scheduled to make a presentation at the BIOCOM Investor Conference, Hyatt Regency La Jolla (CA) on October 26, 2009 at 3:30pm PDT. Dana B. Shinbaum, Vice President, Business Development will provide an overview and discuss the Company's curr...
|
|
Capstone Therapeutics Announces Presentation of Chrysalin(R) (TP508) Pre-Clinical Data At the American College of Surgeons 95th Annual Clinical Conference Demonstrating Significant Benefit in a Model of Acute Heart Disease and Elevated Cholesterol
Oct 13, 2009
|
20.0 KB |
|
| |
TEMPE, Ariz., Oct 13, 2009 (GlobeNewswire via COMTEX News Network) -- Capstone Therapeutics (Nasdaq:CAPS) today announced the presentation of pre-clinical data at the American College of Surgeons 95th Annual Clinical Conference in Chicago, IL, demonstrating significant benefit of Chrysalin(R) (rusalatide acetate or TP508) in a model of acute heart ...
|
|
Capstone Therapeutics Announces Completion of Enrollment for Second of Two AZX100 Phase 2 Studies in Keloid Scarring; Phase 2 Study in Shoulder Surgery Scarring Reaches Enrollment Milestone
Sep 30, 2009
|
16.7 KB |
|
| |
TEMPE, Ariz., Sep 30, 2009 (GlobeNewswire via COMTEX News Network) -- Capstone Therapeutics (Nasdaq:CAPS) announced today the completion of enrollment for the second of its two ongoing AZX100 Phase 2 clinical trials in keloid scarring. The company also announced that its AZX100 Phase 2 clinical trial in trocar site scarring due to arthroscopic shou...
|
|
Capstone Therapeutics Announces Second Quarter 2009 Financial Results
Aug 12, 2009
|
19.6 KB |
|
| |
TEMPE, Ariz., Aug 12, 2009 (GlobeNewswire via COMTEX News Network) -- Capstone Therapeutics (Nasdaq:CAPS), trade name of OrthoLogic Corp. (the "Company"), today announced financial results for the second quarter 2009.
The Company reported a net loss of $3.1 million, or $0.08 per share, for the second quarter 2009, compared to a net loss of $2.8...
|
|
Capstone Therapeutics to Host Conference Call Discussing Second Quarter 2009 Operating Results
Aug 4, 2009
|
15.5 KB |
|
| |
TEMPE, Ariz., Aug 4, 2009 (GlobeNewswire via COMTEX News Network) -- Capstone Therapeutics (Nasdaq:CAPS), trade name of OrthoLogic Corp. (the "Company") will host a conference call and webcast presenting second quarter 2009 operating results on August 12, 2009 at 4:30pm EDT / 3:30pm CDT / 1:30pm PDT. The call may be accessed at 888-215-6825 (domest...
|
|
Capstone Therapeutics Announces Completion of Enrollment for First of Two AZX100 Phase 2 Pilot Studies in Keloid Scarring
Jul 14, 2009
|
16.2 KB |
|
| |
TEMPE, Ariz., Jul 14, 2009 (GlobeNewswire via COMTEX News Network) -- Capstone Therapeutics (Nasdaq:CAPS) announced today the completion of enrollment for the first of its two ongoing AZX100 Phase 2 pilot clinical trials in keloid scarring.
These Phase 2 pilot trials are blinded, placebo controlled, multicenter, parallel group dose ranging stud...
|
|
Capstone Therapeutics Announces First Quarter 2009 Financial Results
May 11, 2009
|
18.3 KB |
|
| |
TEMPE, Ariz., May 11, 2009 (GlobeNewswire via COMTEX News Network) -- Capstone Therapeutics (Nasdaq:CAPS), trade name of OrthoLogic Corp. (the "Company"), today announced financial results for the first quarter 2009.
The Company reported a net loss of $4.1 million, or $0.10 per share, for the first quarter 2009, compared to a net loss of $2.7 m...
|
|
Capstone Therapeutics to Host Conference Call Discussing First Quarter 2009 Operating Results
May 6, 2009
|
15.5 KB |
|
| |
TEMPE, Ariz., May 6, 2009 (GlobeNewswire via COMTEX News Network) -- Capstone Therapeutics (Nasdaq:CAPS), trade name of OrthoLogic Corp. (the "Company") will host a conference call and webcast presenting first quarter 2009 operating results on May 11, 2009 at 4:30pm EDT / 3:30pm CDT / 1:30pm PDT. The call may be accessed at 888-211-7292 (domestic),...
|
|
Capstone Therapeutics Announces Publication of Second Data Group (Elevated Cholesterol) From Chrysalin(r) (TP508) Study Demonstrating Significant Benefit in a Pre-Clinical Model of Acute Heart Disease
Apr 22, 2009
|
19.9 KB |
|
| |
TEMPE, Ariz., Apr 22, 2009 (GlobeNewswire via COMTEX News Network) -- Capstone Therapeutics (Nasdaq:CAPS) today announced publication of results from the second data group of a pre-clinical study demonstrating that Chrysalin(r) (rusalatide acetate or TP508), administered following the onset of ischemia, showed a statistically significant cardioprot...
|
|
Capstone Therapeutics Announces Initiation of Dosing for AZX100 Phase 2 Pilot Study in Keloid Scarring
Apr 3, 2009
|
15.9 KB |
|
| |
TEMPE, Ariz., Apr 3, 2009 (GlobeNewswire via COMTEX News Network) -- Capstone Therapeutics (Nasdaq:CAPS) announced today the initiation of dosing for its AZX100 Phase 2 pilot clinical trial in keloid scarring.
The Phase 2 pilot trial is a blinded, placebo controlled, multicenter, parallel group dose ranging study to evaluate the safety and prel...
|
|
Capstone Therapeutics Announces Publication of First Data Group From Chrysalin(r) (TP508) Study Demonstrating Significant Benefit in a Pre-Clinical Model of Acute Heart Disease
Mar 5, 2009
|
18.3 KB |
|
| |
TEMPE, Ariz., Mar 5, 2009 (GlobeNewswire via COMTEX News Network) -- Capstone Therapeutics (Nasdaq:CAPS) today announced publication of results from the first data group of a pre-clinical study demonstrating that Chrysalin(r) (rusalatide acetate or TP508), administered following the onset of ischemia, showed a statistically significant cardioprotec...
|
|
Capstone Therapeutics Announces Initiation of Dosing for AZX100 Phase 2 Clinical Trial in Dermal Scarring; Management to Host Teleconference and Webcast Today
Feb 10, 2009
|
16.8 KB |
|
| |
TEMPE, Ariz., Feb 10, 2009 (GlobeNewswire via COMTEX News Network) -- Capstone Therapeutics (Nasdaq:CAPS) announced today the initiation of dosing for its AZX100 Phase 2 clinical trial in dermal scarring.
The clinical trial is a Phase 2a double blind, placebo controlled, multi-center dose ranging study to evaluate the safety and preliminary eff...
|
|
Capstone Therapeutics to Host Investor Update Teleconference and Webcast February 10, 2009
Feb 5, 2009
|
15.5 KB |
|
| |
TEMPE, Ariz, Feb 5, 2009 (GlobeNewswire via COMTEX News Network) -- Capstone Therapeutics (Nasdaq:CAPS) will host a teleconference and webcast to discuss operating plans on Tuesday, February 10, 2009 at 4:30pm EST/ 3:30pm CST/ 2:30pm MST/ 1:30pm PST. The call may be accessed at 888-256-9134 (domestic), (+1) 913-312-1387 (international); accompanyin...
|
|
Capstone Therapeutics Announces Chrysalin(r) (TP508, Rusalatide Acetate) Scientific Abstracts to be Presented At the American Society for Cell Biology 48th Annual Meeting; Studies Characterize Integrin Interaction and Biologic Activity
Dec 15, 2008
|
16.2 KB |
|
| |
TEMPE, Ariz., Dec 15, 2008 (GlobeNewswire via COMTEX News Network) -- Capstone Therapeutics (Nasdaq:CAPS) announced today the publication of several abstracts characterizing the science of its novel thrombin peptide Chrysalin(r) (TP508 or rusalatide acetate). The abstracts being presented at the American Society for Cell Biology 48th Annual Meeting...
|
|
Capstone Therapeutics Announces Positive Safety Results in Primary Endpoint From Second AZX100 Phase 1 Clinical Trial in Dermal Scarring; Pharmacologic Signal Shown in Secondary Endpoints
Dec 10, 2008
|
16.4 KB |
|
| |
TEMPE, Ariz., Dec 10, 2008 (GlobeNewswire via COMTEX News Network) -- Capstone Therapeutics (Nasdaq:CAPS) announced today positive safety results were obtained in the second of two planned Phase 1 human clinical trials of AZX100 in dermal / hypertrophic scarring. No serious treatment-emergent adverse events were reported in any subject. Secondary o...
|
|
Capstone Therapeutics Announces Third Quarter 2008 Financial Results
Nov 6, 2008
|
19.3 KB |
|
| |
TEMPE, Ariz., Nov 6, 2008 (GlobeNewswire via COMTEX News Network) -- Capstone Therapeutics (Nasdaq:CAPS), trade name of OrthoLogic Corp. (the "Company"), today announced financial results for the third quarter 2008.
The Company reported a net loss of $3.1 million, or $0.08 per share, for the third quarter 2008, compared to a net loss of $2.4 mi...
|
|
Capstone Therapeutics Receives NASDAQ Notice Temporarily Suspending Minimum Bid Price Rule
Oct 22, 2008
|
15.6 KB |
|
| |
TEMPE, Ariz., Oct 22, 2008 (GlobeNewswire via COMTEX News Network) -- Capstone Therapeutics (Nasdaq:CAPS), trade name of OrthoLogic Corp. ("the Company"), received on August 11, 2008 a letter dated August 8, 2008 from The Nasdaq Stock Market notifying it that for the 30 consecutive business days preceding the date of the letter, the bid price of th...
|
|
|
